ERBB2 and breast cancer: Our results in HER2-negative metastatic breast cancer patients suggested that different dose-intensity regimens of the same chemotherapeutic agent could make a difference in the diversity, composition, and functional structure of gut microbiota, and the presence of specific bacterial species may act as microbial markers associated with drug resistance monitoring and prognostic evaluation.